PANTHERx® Specialty Pharmacy announced today that it has expanded its preferred partnership with Highmark to include Crysvita™ (burosumab-twza). Crysvita™ (burosumab-twza) is the first FDA-approved therapy to treat adults and children ages one year and older with x-linked hypophosphatemia (XLH).  XLH causes low levels of phosphorus in the blood. It leads to impaired bone growth and […]

PANTHERx® Specialty Pharmacy’s Chairman & CEO, Dr. Gordon J. Vanscoy will be presenting a discussion on specialty pharmacy’s evolving role in rare disorders and orphan drugs at the upcoming 7th Orphan Drugs & Rare Diseases Americas West Coast Congress from June 25th – 26th in San Diego, California. The Orphan Drugs & Rare Diseases Global […]

PANTHERx® Specialty Pharmacy is honored to announce our sponsorship of the Soft Bones International Scientific Meeting to promote education and advocacy for hypophosphatasia (HPP). This meeting will host the thought leaders and treatment experts in hypophosphatasia from across the world to promote research of this rare bone disease through awareness and fundraising efforts. The Inaugural […]

Gene therapy isn’t on the horizon anymore; it’s here.  Precision medicine demands a level of personalization that few Specialty Pharmacies are equipped to handle.  PANTHERx®’s pure focus on rare and orphan conditions has propelled the company to the forefront of the industry for program personalization, making it the ideal partner to bring new gene therapies […]

PANTHERx® Specialty Pharmacy is pleased to announce that it has received full reaccreditation from URAC, pursuant to Specialty Pharmacy, Version 3.0. This accreditation is a reflection of PANTHERx®’s unwavering commitment to Uncompromising Quality in our patient care. “It’s necessary for specialty pharmacies to provide a higher level of treatment for patients so desired outcomes are […]